Opening book details…
Can I read Acquired resistance mechanisms to osimertinib: The constant battle on EtoBox?
Acquired resistance mechanisms to osimertinib: The constant battle by Ziad Zalaquett; Maria Catherine Rita Hachem; Yara Kassis; Samir Hachem; Roland Eid; Hampig Raphael Kourie; David Planchard is a Medicine article available to read on EtoBox.
What is Acquired resistance mechanisms to osimertinib: The constant battle about?
Lung cancer is the leading cause of cancer-related mortality worldwide. Detectable driver mutations have now changed the course of lung cancer treatment with the emergence of targeted therapy as a novel strategy that widely improved lung cancer prognosis, especially in metastatic patients. Osimertinib (AZD9291) is an irreversible third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) used to treat stage IV EGFR-mutated non-small-cell lung cancer. It was initially designed to target both EGFR-activating mutations and the EGFR T790M mutation as well, which is the most common resistance mechanism to first- and second-generation EGFR-TKIs. Following the FLAURA trial, osimertinib is now widely used in the first-line setting. However, resistance to osimertinib inevitably develops, with numerous mechanisms leading to its resistance, classified into two main categories: EGFR-dependent and EGFR-independent mechanisms. While EGFR-dependent mechanisms consist mainly of the C797S EGFR mutation, EGFR-independent mechanisms include bypass pathways, oncogenic fusions, and phenotypic transformation, among others. This review summarizes the molecular resistance mecha
Who reads Acquired resistance mechanisms to osimertinib: The constant battle?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Ziad Zalaquett; Maria Catherine Rita Hachem; Yara Kassis; Samir Hachem; Roland Eid; Hampig Raphael Kourie; David Planchard
- Publisher
- Elsevier BV
- Published
- 2023
- Language
- EN
- Field
- Medicine (Health Sciences)